Discover why Eli Lilly and Company is set for a strong 2024 with a robust pipeline, solid financials, and strategic growth ...

Hims & Hers is shifting towards personalized medicine with AI-backed solutions. Find out why HIMS stock is buyable despite ...

It is not sold by Eli Lilly in any oral format. Lexaria's Study was designed to discover whether the active drug within Zepbound® - tirzepatide - could be administered using Lexaria's patented ...

Tirzepatide and semaglutide offer long-term health benefits, but would require discounts to reach $100,000/QALY threshold ...

More consistent accumulation demonstrated in bloodstream over a one-week duration with once-daily DehydraTECH-tirzepatide oral capsules as compared to once-weekly injection of Zepbound®As previously a ...

University of Chicago researchers assessed the long-term health outcomes and cost-effectiveness of four antiobesity ...

The study, referred to as Human Study #3 or GLP-1-H24-3, aimed to determine if tirzepatide, the active drug in Zepbound®, could be effectively delivered into the human bloodstream using Lexaria ...

Share on Pinterest Mounjaro, a tirzepatide drug prescribed for diabetes, could help people without this condition lose 13% of their body weight in the space of 6 months. Image credit: Tatsiana ...

KELOWNA, BC - Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW), a $25.7 million market cap biotech company and leader in drug delivery platforms, has announced promising results from its recent ...